L'importance de la pharmacovigilance en psychiatrie - Le projet AMSP (arzneimittelsicherheit in der psychiatrie)

Revue Medicale de la Suisse Romande

Volumn 120, Issue 2, 2000, Pages 105-109

  Zullino, Daniele ^a   Baumann, Pierre ^a   Grohmann, Renate ^b   Greil, Waldemar ^c  

^a DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

^b UNIVERSITY OF MUNICH   (Germany)

^c Psychiatrische Privatklinik Sanatorium Kilchberg ^*  (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PSYCHOTROPIC AGENT;

ARTICLE; DRUG HYPERSENSITIVITY; DRUG INDUSTRY; DRUG SURVEILLANCE PROGRAM; EPIDEMIOLOGY; GERMANY; HEALTH CARE QUALITY; HUMAN; ORGANIZATION AND MANAGEMENT; PSYCHIATRIC DEPARTMENT; SWITZERLAND;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CAUSALITY; DRUG HYPERSENSITIVITY; DRUG INDUSTRY; GERMANY; HUMANS; PSYCHIATRIC DEPARTMENT, HOSPITAL; PSYCHOTROPIC DRUGS; QUALITY ASSURANCE, HEALTH CARE; SWITZERLAND;

EID: 0034136264     PISSN: 00353655     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Linden M.: Phase IV research and drug utilization observation studies. Pharmacopsychiat., 30: 1-3, 1997.
2. Schäfer H.: Post-approval drug research: objectives and methods. Pharmacopsychiat., 30: 4-8, 1997.
3. Amery W.K.: Why there is a need for pharmacovigilance. Pharmacoep. Drug. Saf., 8: 61-64, 1999.
4. Egberts A.C.G., Veenstra M., de Jongvan den Berg L.T.W.: Antidepressant drug choice for first users in two regions in the Netherlands. Pharm. World Sci., 21: 132-136, 1999.
5. Herbold M.: International guidlines on post-authorisation research and surveillance. Pharmacopsychiat., 30: 62-64, 1997.
6. Linden M., Baier D., Beitinger H., Kohnen R., Osterheider M., Philipp M., Reimitz D.E., Schaaf B., Weber H.J.: Guidlines for the implemetation of drug utilization observation (DUO) studies in psychopharmacological therapy. Pharmacopsychiat., 30: 65-70, 1997.